Changes of macular sensitivity and morphology after pars plana vitrectomy for macular edema with central retinal vein occlusion: A case series

BMC Ophthalmology

Volumn 13, Issue 1, 2013, Pages

  Noma, Hidetaka ^a   Mimura, Tatsuya ^b   Shimada, Katsunori ^c  

^a Tokyo Women s Medical University   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c STATZ Institute Inc   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ANALYSIS OF VARIANCE; ARTICLE; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; ISCHEMIA; MALE; METHODOLOGY; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; VISUAL ACUITY; VISUAL FIELD; VITRECTOMY;

AGED; ANALYSIS OF VARIANCE; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; ISCHEMIA; MACULAR EDEMA; MALE; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; VISUAL FIELDS; VITRECTOMY;

MLCS; MLOWN;

EID: 84873263165     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-13-2     Document Type: Article

References (19)

1. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Noma H, Funatsu H, Mimura T, Harino S, Hori S, Ophthalmology 2009 116 87 93 10.1016/j.ophtha.2008.09.034 19118700
2. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U, Br J Ophthalmol 2008 92 518 522 10.1136/bjo.2007.127282 18211942 (Pubitemid 351497981)
3. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Prager F, Michels S, Kriechbaum K, Georgopoulos M, Funk M, Geitzenauer W, Polak K, Schmidt-Erfurth U, Br J Ophthalmol 2009 93 452 456 10.1136/bjo.2008.141085 19074916
4. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG, Ophthalmology 2011 118 2041 2049 10.1016/j.ophtha.2011.02.038 21715011
5. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 5. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH, Arch Ophthalmol 2009 127 1101 1114 19752419
6. Vitrectomy for macular edema combined with retinal vein occlusion. Tachi N, Hashimoto Y, Ogino N, Doc Ophthalmol 1999 97 465 469 10.1023/A:1002432032354 10896365
7. Functional-morphologic correlates in patients with branch retinal vein occlusion and macular edema. Noma H, Funatsu H, Mimura T, Harino S, Shimada K, Retina 2011 31 2102 2108 10.1097/IAE.0b013e318212e24d 21734622
8. Retinal function and morphology in central retinal vein occlusion with macular oedema. Noma H, Mimura T, Shimada K, Curr Eye Res 2013 38 143 149 10.3109/02713683.2012.724142 22991926
9. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW, Alge CS, Kunze C, Haritoglou C, Kampik A, Retina 2007 27 1004 1012 10.1097/IAE.0b013e3180ed458d 18040236 (Pubitemid 350303999)
10. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, Jian K, Sakamoto I, Nakano K, Yamashita H, Minamoto A, Mishima HK, Am J Ophthalmol 2005 140 256 261 16086947
11. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H, Mishima HK, Graefes Arch Clin Exp Ophthalmol 2006 244 309 315 10.1007/s00417-004-1087-4 16133018
12. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, Hirayama T, Tamura H, Yamashita H, Minamoto A, Mishima HK, Eye 2008 22 42 48 10.1038/sj.eye.6702498 16826241
13. Baseline and early natural history report. The Central Vein Occlusion Study, Arch Ophthalmol 1993 111 1087 1095 7688950
14. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report, Ophthalmology 1995 102 1425 1433 9097788
15. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group, Arch Ophthalmol 1997 115 486 491 9109757
16. Vitrectomy prevents retinal hypoxia in branch retinal vein occlusion. Stefansson E, Novack RL, Hatchell DL, Invest Ophthalmol Vis Sci 1990 31 284 289 2303330 (Pubitemid 20072693)
17. Ocular oxygenation and the treatment of diabetic retinopathy. Stefansson E, Surv Ophthalmol 2006 51 364 380 10.1016/j.survophthal.2006.04.005 16818083 (Pubitemid 43970734)
18. Vitreous inflammatory factors in macular edema with central retinal vein occlusion. Noma H, Funatsu H, Harino S, Mimura T, Eguchi S, Hori S, Jpn J Ophthalmol 2011 55 248 255 10.1007/s10384-011-0016-4 21538003
19. Visual acuity and foveal thickness after vitrectomy for macular edema. Noma H, Funatsu H, Mimura T, Shimada K, Ophthalmologica 2010 224 367 373 10.1159/000313819 20453544